Design, synthesis, and evaluation of some novel N-benzothiazol-2-yl benzamide derivatives as allosteric activators of human glucokinase

HTML Full Text

Reference

Bastaki S. Diabetes mellitus and its treatment. Int J Diabetes Metab, 2005; 13:111-34. https://doi.org/10.1159/000497580
Bowler JM, Hervert KL, Kearley ML, Miller BG. Smallmolecule allosteric activation of human glucokinase in the absence of glucose. ACS Med Chem Lett, 2013; 4(7):580-4. https://doi.org/10.1021/ml400061x
Charaya N, Pandita D, Grewal AS, Lather V. Design, synthesis and biological evaluation of novel thiazol-2-yl benzamide derivatives as glucokinase activators. Comput Biol Chem, 2018; 73:221-9. https://doi.org/10.1016/j.compbiolchem.2018.02.018
Coghlan M, Leighton B. Glucokinase activators in diabetes management. Expert Opin Investig Drugs, 2008; 17(2):145-67. https://doi.org/10.1517/13543784.17.2.145
Efanov AM, Barrett DG, Brenner MB, Briggs SL, Delaunois A, Durbin JD, Giese U, Guo H, Radloff M, Gil GS, Sewing S, Wang Y, Weichert A, Zaliani A, Gromada J. A novel glucokinase activator modulates pancreatic islet and hepatocyte function. Endocrinology, 2005; 146(9):3696-701. https://doi.org/10.1210/en.2005-0377
Ericsson H, Sjoberg F, Heijer M, Dorani H, Johansson P, Wollbratt M, Norjavaara E. The glucokinase activator AZD6370 decreases fasting and postprandial glucose in type 2 diabetes mellitus patients with effects influenced by dosing regimen and food. Diabetes Res Clin Pract, 2012; 98:436-44. https://doi.org/10.1016/j.diabres.2012.09.025
Futamura M, Hosaka H, Kadotani A, Shimazaki H, Sasaki K, Ohyama S, Nishimura T, Eiki J, Nagata Y. An allosteric activator of glucokinase impairs the interaction of glucokinase and glucokinase regulatory protein and regulates glucose metabolism. J Biol Chem, 2006; 281:37668-74. https://doi.org/10.1074/jbc.M605186200
Grewal AS, Beniwal M, Pandita D, Sekhon BS, Lather M. Recent updates on peroxisome proliferator-activated receptor δ agonists for the treatment of metabolic syndrome. Med Chem, 2016a; 12:03-21. https://doi.org/10.2174/1573406411666150525105826
Grewal AS, Bhardwaj S, Pandita D, Lather V, Sekhon BS. Updates on aldose reductase inhibitors for management of diabetic complications and non-diabetic diseases. Mini Rev Med Chem, 2016b; 16(2):120-62. https://doi.org/10.2174/1389557515666150909143737
Grewal AS, Dua, JS, Prasad DN, Kharb R, Lather V. Design, synthesis and evaluation of novel 3,5-disubstituted benzamide derivatives as allosteric glucokinase activators. BMC Chem, 2019a; 13:2. https://doi.org/10.1186/s13065-019-0532-8
Grewal AS, Kharb R, Dua JS, Lather V. Molecular docking assessment of N-heteroaryl substituted benzamide derivatives as glucokinase activators. Asian J Pharm Pharmacol, 2019b; 5(1):129-36. https://doi.org/10.31024/ajpp.2019.5.1.18
Grewal AS, Kharb R, Prasad DN, Dua JS, Lather V. N-Pyridin2-yl benzamide analogues as allosteric activators of glucokinase: design, synthesis, in vitro, in silico and in vivo evaluation. Chem Biol Drug Des, 2019c; 93:364-72. https://doi.org/10.1111/cbdd.13423
Grewal AS, Lather V, Pandita D, Bhayana G. Synthesis, docking and biological evaluation of phenylacetic acid and trifluoromethylphenyl substituted benzamide derivatives as potential PPARδ agonists. Lett Drug Des Discov, 2017; 14:1239-51. https://doi.org/10.2174/1570180814666170327164443
Grewal AS, Sekhon BS, Lather V. Recent updates on glucokinase activators for the treatment of type 2 diabetes mellitus. Mini Rev Med Chem, 2014; 14:585-602. https://doi.org/10.2174/1389557514666140722082713
Kohei K. Pathophysiology of type 2 diabetes and its treatment policy. Japan Med Assoc J, 2010; 53:41-6.
Lagorce D, Bouslama L, Becot J, Miteva MA, Villoutreix BO. FAF-Drugs4: free ADME-tox filtering computations for chemical biology and early stages drug discovery. Bioinformatics, 2017; 33:3658-60. https://doi.org/10.1093/bioinformatics/btx491
Lei L, Liu Q, Liu S, Huan Y, Sun S, Chen Z, Li L, Feng Z, Li Y, Shen Z. Antidiabetic potential of a novel dual-target activator of glucokinase and peroxisome proliferator activated receptor-γ. Metab Clin Exp, 2015; 64(10):1250-61. https://doi.org/10.1016/j.metabol.2015.06.014
Matschinsky FM, Zelent B, Doliba N, Li C, Vanderkooi JM, Naji A, Sarabu R, Grimsby J. Glucokinase activators for diabetes therapy. Diabetes Care, 2011; 34:S236-43. https://doi.org/10.2337/dc11-s236
McKerrecher D, Steven A. Design and development of the glucokinase activator AZD1656. In: Abdel-Magid AF, Pesti JA, Vaidyanathan R (eds.). Complete accounts of integrated drug discovery and development: recent examples from the pharmaceutical industry. Washington, DC: American Chemical Society, pp 185-220, 2018. https://doi.org/10.1021/bk-2018-1307.ch007
Miteva M, Guyon F, Tufféry P. Frog2: efficient 3D conformation ensemble generator for small compounds. Nucl Acids Res, 2010; 38: W622-7. https://doi.org/10.1093/nar/gkq325
Miteva M, Violas S, Montes M, Gomez D, Tuffery P, Villoutreix B. FAF-drugs: free ADME/Tox filtering of compound collections. Nucl Acids Res, 2006; 34:W738-44. https://doi.org/10.1093/nar/gkl065
Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexiblity. J Comput Chem, 2009; 16: 2785-91. https://doi.org/10.1002/jcc.21256
Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: a review of current trends. Oman Med J, 2012; 27:269-73. https://doi.org/10.5001/omj.2012.68
Pal M. Medicinal chemistry approaches for glucokinase activation to treat type 2 diabetes. Curr Med Chem, 2009a; 16(29):3858-74. https://doi.org/10.2174/092986709789177993
Pal M. Recent advances in glucokinase activators for the treatment of type 2 diabetes. Drug Discov Today, 2009b; 14:784-92. https://doi.org/10.1016/j.drudis.2009.05.013
Park K, Lee BM, Hyun KH, Lee DH, Choi HH, Kim H, Chong W, Kim KB, Nam SY. Discovery of 3-(4-methanesulfonylphenoxy)-N-[1- (2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)- benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus. Bioorg Med Chem, 2014; 22(7):2280-93. https://doi.org/10.1016/j.bmc.2014.02.009
Park K, Lee BM, Kim YH, Han T, Yi W, Lee DH, Choi HH, Chong W, Lee CH. Discovery of a novel phenylethyl benzamide glucokinase activator for the treatment of type 2 diabetes mellitus. Bioorg Med Chem Lett, 2013; 23(2):537-42. https://doi.org/10.1016/j.bmcl.2012.11.018
Perseghin G. Exploring the in vivo mechanisms of action of glucokinase activators in type 2 diabetes. J Clin Endocrinol Metab, 2010; 95(11):4871-3. https://doi.org/10.1210/jc.2010-2049
Pike KG, Allen JV, Caulkett PWR, Clarke DS, Donald CS, Fenwick ML, Johnson KM, Johnstone C, McKerrecher D, Rayner JW, Walker RP, Wilson I. Design of a potent, soluble glucokinase activator with increased pharmacokinetic half-life. Bioorg Med Chem Lett, 2011; 21(11):3467-70. https://doi.org/10.1016/j.bmcl.2011.03.093
Pires DE, Blundell TL, Ascher DB. pkCSM: Predicting smallmolecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem, 2015; 58(9):4066-72. https://doi.org/10.1021/acs.jmedchem.5b00104
Pires DE, Kaminskas LM, Ascher DB. Prediction and optimization of pharmacokinetic and toxicity properties of the ligand. Methods Mol Biol, 2018; 1762:271-84. https://doi.org/10.1007/978-1-4939-7756-7_14
Rathee D, Grewal AS, Dureja H, Lather V. Enzymatic inhibitory activity of iridoid glycosides from Picrorrhiza kurroa against matrix metalloproteinases: correlating in vitro targeted screening and docking. Comput Biol Chem, 2019; 78:28-36. https://doi.org/10.1016/j.compbiolchem.2018.10.017
Salgueiro A, Folmer V, da Rosa H, Costa M, Boligon A, Paula F, Roos D, Puntel G. In vitro and in silico antioxidant and toxicological activities of achyrocline satureioides. J Ethnopharmacol, 2016; 194:6-14. https://doi.org/10.1016/j.jep.2016.08.048
Singh R, Lather V, Pandita D, Judge V, Arumugam KN, Grewal AS. Synthesis, docking and antidiabetic activity of some newer benzamide derivatives as potential glucokinase activators. Lett Drug Des Discov, 2017; 14:540-53. https://doi.org/10.2174/1570180813666160819125342
Sjostrand M, Ericsson H, Hartford M, Norjavaara E, Eriksson JW. Pharmacodynamic effects of the oral glucokinase activator AZD6370 after single doses in healthy volunteers assessed with euglycaemic clamp. Diabetes Obes Metab, 2013; 15(1):35-41. https://doi.org/10.1111/j.1463-1326.2012.01672.x
Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comput Chem, 2010; 31:455-61. https://doi.org/10.1002/jcc.21334
Wang Z, Shi X, Zhang H, Yu L, Cheng Y, Zhang H, Zhang H, Zhou J, Chen J, Shen X, Duan W. Discovery of cycloalkyl-fused N-Thiazol2-yl-benzamides as tissue non-specific glucokinase activators: design, synthesis, and biological evaluation. Eur J Med Chem, 2017; 139:128-52. https://doi.org/10.1016/j.ejmech.2017.07.051

Article Metrics

Similar Articles

Related Search

By author names

Arora S [PubMed] [Google Scholar ]
Grewal A S [PubMed] [Google Scholar ]
Sharma N [PubMed] [Google Scholar ]
Arora K [PubMed] [Google Scholar ]
Dhalio E [PubMed] [Google Scholar ]
Singh S [PubMed] [Google Scholar ]